In silico cancer immunotherapy trials uncover the consequences of therapyspecific response patterns for clinical trial design and outcome

Jeroen Creemers^{1,2}, Ankur Ankan³, Kit C.B. Roes⁴, Gijs Schröder³, Niven Mehra⁵, Carl G. Figdor^{1,2}, I. Jolanda M. de Vries¹, Johannes Textor^{1,3#}

¹ Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

² Oncode Institute, Nijmegen, The Netherlands

³ Data Science group, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands

⁴ Department of Health Evidence, Section Biostatistics, Radboudumc, Nijmegen, The Netherlands

⁵ Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands

Corresponding author email address: [#]johannes.textor@ru.nl

Abstract

Late-stage cancer immunotherapy trials often lead to unusual survival curve shapes, like delayed curve separation or a plateauing curve in the treatment arm. It is critical for trial success to anticipate such effects in advance and adjust the design accordingly. Here, we use in silico cancer immunotherapy trials - simulated trials based on three different mathematical models - to assemble virtual patient cohorts undergoing late-stage immunotherapy, chemotherapy, or combination therapies. We find that all three simulation models predict the distinctive survival curve shapes commonly associated with immunotherapies. Considering four aspects of clinical trial design - sample size, endpoint, randomization rate, and interim analyses - we demonstrate how, by simulating various possible scenarios, the robustness of trial design choices can be scrutinized, and possible pitfalls can be identified in advance. We provide readily usable, web-based implementations of our three trial simulation models to facilitate their use by biomedical researchers, doctors, and trialists.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity. It is made available under a CC-BY 4.0 International license .

Introduction

Immunotherapy is revolutionizing the treatment landscape for patients with advanced cancers. While the number of 2 immuno-oncology drugs under investigation is rising rapidly – around 4700 agents are currently in the development 3 pipeline – the need to further improve patient outcomes remains high [1]. Well-designed immunotherapy trials are cru-4 cial to establish advances in clinical outcomes robustly. Unfortunately, the odds for cancer treatments to successfully 5 pass the development pipeline are unfavorable, and only a minority of the treatments (5-10%) ultimately obtain market 6 approval [2–4]. Even for cancer therapies that do reach late-stage development, approval rates remain modest at around 7 27% [5]. The primary reason in most of these trials (i.e., 63.7%) is failure to demonstrate efficacy [5], which can be 8 partly attributed to suboptimal trial design choices based on overly optimistic assumptions of the treatment effect. Such 9 assumptions may be used to erroneously justify low numbers of patients or inappropriate endpoints and lower the power 10 of these trials [5,6]. 11

Immunotherapy trials raise complex design questions, and conventional design methods are not always a good match to the unique characteristics of immunotherapies [7]. There is a very broad spectrum of therapies based on various molecular mechanisms – ranging from immunomodulators to cell therapies, cancer vaccines, oncolytic viruses, and CD3-targeted bispecific antibodies – that can lead to unusual toxicity profiles, response patterns, and survival kinetics [8–10]. These observations render a "one-design-fits-all" approach futile and stress the need for designs that are tailored to immunotherapy

- ¹⁷ or even combination therapies.
- ¹⁸ Immunotherapies are known to induce a delayed clinical effect and long-term overall survival (OS) in only a subset of ¹⁹ patients [11]. The survival curve reflects these phenomena by a delayed curve separation and a plateau of the treatment ²⁰ arm at later stages of the trial [12]. These characteristics violate a fundamental premise that underlies the design of many ²¹ trials: the proportional hazard assumption (PHA) – essentially stating that the treatment effect should remain constant over ²² time [13]. As a result, immunotherapy trials based on this principle can have an overestimated power [12, 13] and require ²³ a longer follow-up to demonstrate efficacy than initially planned [12], increasing the likelihood of a negative trial.
- ²⁴ These issues led to the development of innovative methods such as novel radiological criteria to quantify tumor responses
- ²⁵ [9, 14, 15], (surrogate) endpoints to capture unique survival kinetics [10, 16–19], biomarkers to enrich for patients more
- likely to respond to treatment [20–23], and statistical methods to retain a trial's power in the presence of unusual survival
- kinetics [24–26]. Despite the multitude of available methods, it is difficult to predict trial outcomes in advance and select
- the methodology accordingly. The stakes are high: a trial design built on accurate predictions of the response kinetics is
- ²⁹ more likely to be positive, whereas misjudgment could result in a negative trial, potentially compromising patient benefit,
- ³⁰ vast amounts of work, and (public) research funds.
- In this study, we use late-stage *in silico* cancer immunotherapy trials to investigate how design decisions affect the trial outcome in the context of cancer immunotherapy, possibly combined with chemotherapy. The mechanism-based nature
- of these trials allows researchers to translate cellular processes in the tumor microenvironment and immunotherapeutic
- interventions thereon into predicted response patterns, survival kinetics, and trial outcomes. An *in silico* immunotherapy
- trial is based on explicit biological assumptions and provides an intuitive means to predict risk profiles and treatment
- ³⁶ efficacy. Moreover, it equips researchers with a tool to scrutinize trial designs and analysis strategies of upcoming trials
- ³⁷ in advance to identify potential risks and pitfalls.
- We use three different simulation models to perform our *in silico* trials, based on work by ourselves [27] and other authors [28, 29]. Despite considerable differences, all models replicate late-stage immunotherapy or combination trials
- reasonably well and capture their typical survival kinetics. Then, we demonstrate various applications of such trial simu-
- ⁴¹ lations, including the ability to scrutinize a clinical trial's design and sample size calculations based on a range of predicted
- ⁴² possible outcomes. Finally, we illustrate the consequences of (not) considering immunotherapy-specific response patterns
- ⁴³ in settings selected for educational purposes, such as selecting survival endpoints and randomization ratios of upcoming
- trials and planning interim analyses.

perpetuity. It is made available under a CC-BY 4.0 International license .

45 Results

46 Generating trial populations based on tumor-immune dynamics

47 We used *in silico* cancer immunotherapy trials based on mechanistic simulations of cancer-immune dynamics to investigate

the consequences of immunotherapy-specific response patterns on trial design principles [26]. The virtual patients in these

49 trials are simulated with ODE models, which describe disease courses based on assumptions about interactions between

⁵⁰ tumor cells and the immune system [26]. In this paper, we will focus on simulating two years of follow-up after treatment

- while it is straightforward to consider longer follow up times with *in silico* trials, a two-year time frame is common for

⁵² contemporary immunotherapy trials [30–32].

To investigate the extent to which our simulation results depend on specific modeling choices, we use three different ODE 53 models. Model 1 (M1) describes the following tumor-immune dynamics in the tumor microenvironment: immunogenic 54 tumor growth leading to priming and clonal expansion of naïve T cells, migration of effector T cells to the tumor microen-55 vironment, and formation of tumor-immune complexes to enable tumor cell killing (see Methods; Figure 1A). We simulate 56 treating these patients with immune checkpoint inhibitors (ICI), chemotherapy, or both. ICI increase the T cell killing rate 57 and directly affect the tumor-immune dynamics. Chemotherapy has a cytotoxic effect on the tumor, slowing its growth. A 58 detailed description of the model, including the rationale for parameter selection, has been published previously [26]. In 59 contrast, model 2 (M2) does not represent T cells migration between lymph nodes and tumor microenvironment; however, 60 it does contain an explicit representation of antigen-presenting cells (APCs) [33]. Finally, Model 3 (M3) does not contain 61 either T cell migration or APCs, but it does take T cell exhaustion into account. Another important difference between 62 the models lies in how tumor growth is represented: M1 uses a size-dependent growth rate, M3 a resource-constrained 63 growth rate (logistic growth), and M2 uses unlimited exponential growth. 64

Regardless of model specifics, in silico clinical trials describe cancer outcomes on three levels: (1) a cellular level, (2) 86 a patient level, and (3) a trial population level. Cellular interactions in the tumor microenvironment are translated into 87 clinical trial outcomes as follows: firstly, the ODE model is implemented, and model parameters that vary between patients 88 are selected by fitting to existing survival data (Figure 1B; see Methods). Next, individualized disease trajectories – 89 either treated or untreated – of cancer patients are generated (Figure 1C). Eventually, patients are randomized into two 90 cohorts to resemble conventional phase III trials: a control group (either placebo or chemotherapy) and a treatment group 91 (immunotherapy, chemoimmunotherapy, or induction chemotherapy followed by immunotherapy; Figure 1D). Since the 92 cellular dynamics (e.g., tumor burden over time or the efficacy of T cell killing) and survival outcomes of these patients are 93 known and can be modified, in silico clinical trials are suited to answer questions like:"Assuming that a novel treatment 94 increases T cell killing 5-fold, how does this translate to a survival benefit in patients? Moreover, how many patients are 95 needed to establish this benefit in a clinical trial? When should one analyze the results?" (Figure 1E). 96 Despite their differing mechanisms, the models generate qualitatively similar predictions (Figure 2): tumors grow at real-97

⁹⁸ istic speeds and are usually not cleared by the immune system without therapeutic intervention. In the models, therapeutic

⁹⁹ interventions can slow or even reverse tumor growth, in principle leading to two major contrasting outcomes: death or

¹⁰⁰ long-term survival. However, there is a unique effect in M3 where even after treatment and growth reverse, the tumor

¹⁰¹ burden keeps oscillating over time, leading to regular self-resolving recurrences. While this may not be entirely realistic,

¹⁰² it is not an issue for our purpose as we shall focus on the initial growth trajectory of the tumor preceding and up to 2 years

¹⁰³ after treatment, and recurrences happen after that.

¹⁰⁴ In silico late-stage immunotherapy trials yield realistic survival outcomes

To investigate whether our *in silico* models can generate realistic survival curves as observed in late-stage immunotherapy 105 trials, we fitted the models to three different datasets: (1) the NCCTG lung cancer survival dataset [34]; (2) the CA184-024 106 trial (ipilimumab + dacarbazine vs. dacarbazine in previously untreated metastatic melanoma [35]); and (3) the CheckMate 107 066 trial (nivolumab + placebo vs. dacarbazine + placebo in treatment-naive metastatic melanoma patients without BRAF 108 mutation [36]). The choice for these trials is based on the size of the trials and the maturity of the data. The follow-up 109 of the CA184-024 trial and the CheckMate 066 trial were five and three years, respectively. As the last two datasets 110 were not publicly available, we extracted the data using image digitization (see Methods). As a reference for the in silico 111 trials, we visualized the Kaplan-Meier estimators of these datasets (Figure 3A). Both trials were digitized correctly, as 112 reflected by the nearly identical risk tables compared to the original manuscripts [35, 36]. Next, we fitted the tumor 113 growth rate distributions and treatment effect parameters for chemotherapy and immunotherapy s (NCCTG: 3 parameters; 114 immunotherapy trials: 4 parameters) to these datasets (M1: Figure 3B; M2, M3: Supplementary Figure S1). For the 115 CA184-024 and CheckMate 066 trials, the simulated patients were treated with ICI upon diagnosis, increasing their T cell 116 killing rates. For simplicity, we did not simulate dropout or censoring in the trials shown in this paper, although it could 117 be added to the simulation. Model M1 achieved satisfactory fits to all datasets. However, M2 and M3 had difficulties 118 fitting the CheckMate 066 data, with M2 predicting more rapid death in the control arm and M3 predicting a cross-over 119 of survival curves. M3 also had difficulties fitting the other two datasets, as its survival curves plateaued from 12 months 120



Figure 1: In silico late-stage immunotherapy trials and their applications (A) Cellular interactions between a tumor 65 and the immune system as implemented in ODE model M1 (Methods). This model describes immunogenic tumor growth 66 leading to a T cell response originating from lymph nodes. Disease courses in patients can be steered by immunotherapy, 67 chemotherapy, or a combination of both. Parameters: α = naive T cell priming rate, δ = effector T cell death rate, ξ = 68 effector T cell killing rate, ρ = tumor growth rate, ρ_s = effector T cell proliferation rate, and m_s = effector T cell migration 69 rate. (B) After implementation, we used survival data from clinical trials to fit some of the model parameters. (C) Patients 70 received either no treatment (placebo), chemotherapy, immunotherapy, or both. Disease trajectories based on tumor-71 immune dynamics were simulated for each patient, resulting in individual survival outcomes. (D) Subsequently, cohorts 72 of patients were constructed based on the fitted parameters to simulate actual immunotherapy trials. (E) Applications of 73 such trials include predicting possible survival outcomes of trials, estimating sample sizes needed for a range of scenarios, 74 and investigating endpoints, randomization ratios, and the timing of interim analyses. 75



76

Figure 2: Simulating immunotherapy responses using different mathematical models. Each simulation starts with a 77 single malignant cell that establishes a tumor. Without treatment, this tumor grows to a lethal volume (upper horizontal 78 line) over the course of several months. Treatment is started when the tumor reaches a size of 65×10^8 cells (lower 79 horizontal line). Immunotherapy is implemented in each model by increasing the rate at which T cells kill tumor cells; 80 in M2, the death rate of T cells is additionally decreased by the same factor. The treatment effect sizes are chosen per 81 model such that there is a partial response (orange, leading to prolonged survival) or a complete response (red, leading to 82 tumor eradication). The recurrence of the tumor in M3 is a consequence of the model's equations, which lead to oscillating 83 dynamics of the tumor burden rather than complete eradication in the complete response regime. Arrows indicate start of 84 treatment. 85





Figure 3: Fitting in silico cancer immunotherapy trial models to actual data to simulate realistic survival curves. 132 (A) Kaplan-Meier estimators of the NCCTG, CA184-024, and CheckMate 066 trials. While the NCCTG dataset is pub-133 licly available [34], the others are carefully reconstructed survival curves based on digitized data from their respective 134 manuscripts [35], [36]. (B) Trial simulations can generate realistic survival curves as observed in actual immunotherapy 135 trials. Specifically, typical immunotherapy-related survival curve shapes – such as a delayed curve separation and a plateau 136

in the treatment arm – arise from these simulations as emergent behavior. 137

after treatment onwards. While the fit of all models can be improved by allowing more parameters to vary, we chose to 121 keep the number of fitted parameters small to investigate the consequences of such issues on our downstream analyses. 122

Hence, our in silico trials couple the disease mechanism and mechanistic treatment effect to a predicted clinical trial 123 outcome. By allowing model parameters to vary between patients, such models can be fitted to existing clinical trial data. 124

Whether a good fit can be achieved depends on the model assumptions and the number of parameters that are allowed to 125 vary. In our case, models M1 and M2 were able to fit the three datasets reasonably well, with M3 showing a substantially 126

worse fit. 127

Interestingly, although not incorporated explicitly, the models reproduced hallmark survival curve features arising as a 128 consequence of the interaction between tumor and immune cells typically seen in immunotherapy trials: a delayed curve 129 separation and a plateau of the survival curve of the treatment arm at later stages of the trial (last two columns in Figure 3B 130 and Supplementary Figure S1). 131

In silico immunotherapy trials predict immunotherapy-specific response patterns 138

The design and the success rate of any clinical trial depends, among others, on a realistic predictions of the shape of 139 the survival curves and the distribution of clinical outcomes. For late-stage immunotherapy trials, commonly observed 140 immunotherapy-induced response patterns are a delayed curve separation and a plateauing tail of the survival curve of the 141 treatment arm (Figure 3). These characteristic survival curve shapes violate a vital premise of many clinical trials: the 142 proportional hazard assumption (PHA). The PHA states that the "instantaneous death rate" of a patient (i.e., the hazard 143 rate) in both arms of the trial should be proportional, resulting in a constant hazard ratio. Many traditional design methods, 144 ranging from sample size calculations to outcome analyses, are based on this convenient assumption. For late-stage 145 immunotherapy trials, this induces two problems: (1) while a violation of the PHA needs to be addressed during trial 146 planning, the hazard rates – and an eventual violation of the PHA – becomes available only after the trial; and (2) if a trial 147 does not adhere to a PHA, what will be the shape of the survival curve? Especially in an era where treatment and control 148 arm regimens are becoming increasingly complex, adjusting the design and analysis methods to various survival curve 149

perpetuity. It is made available under a CC-BY 4.0 International license .

150 shapes is challenging.

In silico clinical trials can provide principled predictions about possible shapes of the survival curve, including the under-151 lying hazard rates and hazard ratios, before trial execution. We generated such survival predictions using the models -152 fitted to the CA184-024 data (Table 3) – and changed the treatment effect parameters according to the simulated scenario. 153 A traditional scenario would be a trial in which patients are randomized 1:1 to mono-chemotherapy or placebo. Given the 154 direct chemotherapy effect, the PHA is generally assumed to hold for these trials. An *in silico* trial in which chemotherapy 155 reduces the tumor growth rate for the entire trial duration indeed replicates these assumptions (Supplementary Figure S2): 156 the survival curves separate from the start of the trial, and the hazard ratio remains roughly constant over time. However, 157 what happens if the chemotherapy effect does not last for the entire trial but for - maybe more realistically - 6 months? 158 For M1 and M2, the initial proportional separation of the survival curves is followed by a parallel decay and eventual 159 convergence of both curves, leading to an early but transient survival benefit for the chemotherapy arm (Figure 4A, B). 160 For M3, the chemotherapy effect estimated from the CA184-024 data is more profound and instead induces a permanent 161 response (Figure 4C). Hence, substantial deviations from the PHA are observed in all cases, even for seemingly simple 162 chemotherapy trials. Also, a violated PHA becomes immediately apparent when considering a more contemporary sce-163 nario of immunotherapy combined with chemotherapy compared to chemotherapy alone: through approximately the first 164 six months, the hazard rates remain constant over time, but after that, they start to decline in the immunotherapy group 165 (cyan line), yielding a non-constant hazard ratio over time (Figure 4D). 166 The flexibility of in silico trials lies in their ability to incorporate complex treatment regimens. For example, let us assume 167

¹⁶⁶ one would be interested in estimating the survival curves and underlying hazard ratio over time of an immunotherapy + ¹⁶⁸ placebo-chemotherapy vs. chemotherapy + placebo-immunotherapy trial (**Figure 4E**) or a trial with induction chemother-¹⁷⁰ apy followed by immunotherapy vs. immunotherapy (**Figure 4F**). Mechanism-based immunotherapy trials translate bi-¹⁷¹ ological assumptions regarding the disease and treatment effects into survival curves (including its hazard rate/ratio esti-¹⁷² mates). The resulting survival curve shapes, such as crossing survival curves (**Figure 4E**) or a temporary curve separation ¹⁷³ (**Figure 4F**), may be hard to predict otherwise and can be detrimental to the trial outcome if addressed appropriately.

We emphasize that different models can generate different predictions depending on model assumptions and parameters, as seen in our chemotherapy vs. placebo examples (**Figure 4A, B, C**). Conversely, however, even substantially different models can agree on the essential aspects of the predicted survival curves. For example, despite their differences, our three models all predict the characteristic delayed curve separation of immunotherapy trials (**Figure 4D, Supplementary**

¹⁷⁸ Figure S3, Supplementary Figure S4).

190

¹⁹¹ Using *in silico* trials to select an appropriate outcome metric for measuring a treatment's clinical ¹⁹² effect

A key design decision in a clinical trial is which effect size metric to use to define treatment success. Two common choices are the overall hazard ratio, which is affected by the entire survival data of the trial, and a survival endpoint such as 2-year overall survival (OS), which only depends on the specifically defined time-point. When there is no solid clinical rationale to prefer one effect size measure over the other, statistical considerations such as power become important. To investigate the consequences of choosing hazard ratio or 2-year OS as the study effect size in different immunotherapy scenarios, we determined the power of *in silico* trials by conducting simulations at varying study population sizes.

A potential advantage of using the hazard ratio is its use of the entire survival curve, which can increase power when the 199 PHA is met and detect transient effects even if the PHA is not met. Indeed, when investigating the power of the transient 200 chemotherapy effect generated by model M1 (Figure 4A), we found the power to be much greater when using the hazard 201 ratio compared to the power to detect the minimal difference in survival still found after 2 years. The opposite was true 202 when investigating the chemoimmunotherapy vs. immunotherapy scenario using M2 (Figure 4B): the power of trials that 203 used the hazard ratio lagged far behind the power to detect a 2-year survival endpoint, as a consequence of the considerable 204 violation of the PHA in this scenario. Indeed, when considering the persistent chemotherapy effect generated by model M3 205 (Figure 4C), a scenario with a substantially lower variation of the hazard ratio, we found the power to be more comparable. 206 although the hazard ratio still had a meaningful advantage. When using M3 to investigate the chemoimmunotherapy vs. 207 208 immunotherapy scenario, the choice of endpoint made hardly any difference (Supplementary Figure S5).

These results illustrate the critical importance of choosing an appropriate effect size to measure the clinical outcome, which in turn strongly depends on the shape of the survival curves. For established treatments, investigators can rely on their experience or published results to make an appropriate choice; however, the expected survival curve shape might be very uncertain for novel immunotherapies or combinations of existing immunotherapies. In such cases, running various *in silico* trials would help investigators prepare for different plausible scenarios and choose a robust trial design. In our examples, the models agreed that hazard ratio would be a suitable effect size for a chemotherapy vs. placebo trial even if the PHA does not entirely hold, whereas 2-year OS would be appropriate for the chemoimmunotherapy vs. immunotherapy case

216 (Supplementary Figure S5).



Figure 4: In silico clinical trials can predict immunotherapy-specific survival patterns based on biological assump-179 tions. (A-F) Examples of 1:1 randomized trials with various (treatment) regimens (n=600 per arm). (A-C) A traditional 180 chemotherapy trial (vs. placebo) only shows a proportional hazard ratio when the biological treatment effect targets the tu-181 mor directly and remains constant over time (compare to Supplementary Figure S2). (D) An in silico immunotherapy trial 182 elicits typical immunotherapy-induced survival curve shapes (i.e., delayed curve separation) and violates the proportional 183 hazard assumption. (E-F) More intricate treatment or control regimens -(D) immunotherapy + chemotherapy-placebo vs. 184 chemotherapy + immunotherapy-placebo, or (E) induction chemotherapy followed by immunotherapy vs. immunother-185 apy – induce more complex survival patterns, including (E) crossing survival curves or (F) only a temporary separation 186 of the survival curves. Horizontal bars underneath the survival curves indicate the duration of the treatment effect (T =187 treatment, C = control). The red dot in column three indicates the hazard ratio averaged over the entire trial. Shading: 188 95% CIs. 189



Figure 5: Immunotherapy-specific survival curve shapes critically determine a trial's power to detect different treatment effects. We analyzed the power of *in silico* trials to detect a difference in 2-year OS (black lines) or a hazard ratio <1 (red lines) for (A) chemotherapy vs. placebo (transient effect, M1); (B) chemoimmunotherapy vs. chemotherapy (M2); and chemotherapy vs. placebo (long-term effect; M3). Choosing an inappropriate effect size for the response pattern at hand leads to a significant reduction in trial power, greatly reducing the probability of success. The chemotherapy effect for M3 was set to a 20% reduction in growth rate to simulate a more subtle effect; all other parameters were set to the values fitted to the CA184-024 data. Error bars: 95% CIs.

217 In silico trials can help to choose endpoints and randomization ratios before trial execution

Clearly, the success rate of novel immunotherapy trials depends on more than its sample size alone. To establish an OS 218 benefit of the treatment arm, it is crucial to analyze the trial once the data have reached a certain maturity - i.e., the 219 treatment needs to be granted sufficient time to induce a survival benefit. We assumed that a delayed curve separation 220 in immunotherapy trials would prolong the follow-up needed to establish an OS benefit of immunotherapy and thereby 22 defer reaching maturity of the trial data. If the therapy is effective, data maturity can be regarded as the time point when 222 a treatment effect can be observed. Hence, an optimal trial endpoint would be the earliest time at which this treatment 223 effect can be detected with sufficient power. Therefore, we analyzed the power of differently sized trials with respect 224 to their OS endpoint. Herein, we distinguished trials that were subject or were not subject to a delayed curve separation 225 (immunotherapy and chemotherapy, respectively). In a classic chemotherapy trial, the treatment effect translates directly to 226 a survival benefit in the treatment arm - the survival curves separate from the start. Therefore, the highest power is obtained 227 after the total duration of the treatment effect (Figure 6A, panel 1). In this case, the treatment effect lasts for six months, 228 leading to the 6-months OS as the endpoint with the highest power. The delayed curve separation in immunotherapy trials 229 renders it futile to analyze OS data early on in the trial (Figure 6B, panel 1). A practical ramification is that in the presence 230 of a delayed curve separation, the trial requires a sufficiently long follow-up and an adequate size to gain power and detect 231 immunotherapy-specific treatment effects. Mechanism- and simulation-based power calculations with in silico trials can 232 consider these specific survival curve features when determining the sample size for upcoming trials. 233

Given the observation that both the size of an immunotherapy trial and its endpoint heavily influence the probability of finding the survival benefit of interest, we presumed that increasing the size of the treatment arm – i.e., an unequal randomization scheme – would similarly affect the power. Instead of varying the study size, we now varied the randomization ratio (second panel of **Figure 6A/B**). Interestingly, while the power logically depended on the OS endpoint, the randomization ratio did not greatly affect the power (**Figure 6B**). Considering that an unequal treatment allocation may provide ethical benefits, we confirm that the randomization ratio in immunotherapy trials is of secondary importance compared to its size or primary OS endpoint.

In summary, our *in silico* immunotherapy trials replicate existing insights from trial design as to how violation of the PHA affects power and analysis choices. Our ability to directly translate biological assumptions on treatment mechanisms into survival curve shapes allows the trialist to reason deliberately about whether such violations of the PHA would or would not be expected in their specific trial design and how the problem could be addressed if it arises.

245 Simulating interim analyses to evaluate the trade-off between patient benefit and trial resources

We have observed a clear trade-off between the power of an immunotherapy trial on the one hand, and the primary OS endpoint, and correspondingly the data maturity, on the other. Luckily, the two are not entirely mutually exclusive: interim analyses have been developed for ethical purposes to establish positive or harmful treatment effects early. However, there is a catch: the necessity to control for multiple testing at each interim analysis lowers the significance threshold on the final analysis to maintain the same overall type I error rate. This raises the question: "How many interim analyses should



Figure 6: In silico trials guide decisions on OS endpoints and randomization ratios of upcoming immunotherapy trials. (A-B) In silico trials can be used to find the optimal endpoint (panel 1) or randomization ratio (panel 2) of novel trials. (A) Since the survival curves in classical chemotherapy trials separate from the trial onset, the highest power – and optimal endpoint - is obtained at the end of the treatment interval (i.e., after six months in this example; see Figure 4A). Although less influential, a similar observation can be made for randomization ratios (study size panel 2: 300 patients). (B) Delayed curve separation in immunotherapy trials emphasizes that a premature final analysis of the primary OS endpoint is detrimental to the trial outcome. These trials permit validating the pre-specified survival outcomes of novel trials a priori. Commonly selected randomization ratios do not seem to be heavily influenced by immunotherapy-specific response patterns (study size panel 2: 1200 patient). Trial characteristics are similar to Figure 4A/D. All simulations performed using M1. Error bars: 95% CIs.

perpetuity. It is made available under a CC-BY 4.0 International license .

you plan, and when should you plan them?" Again, well-founded answers to such questions can be obtained with the help 25 of *in silico* immunotherapy trials. To illustrate this, we used M1 to simulate 1000 immunotherapy trials with 1200 patients 252 per trial, randomized 1:1 over immunotherapy with a strong treatment effect or a placebo (Figure 7A). In the absence 253 of interim analyses, the vast majority of the trials are predicted to end up positive. Adding interim analyses (O'Brien-254 Fleming approach) to the equation induces a trade-off. On the one hand, increasing the number of equally-spaced interim 255 analyses increases the probability of early detecting a positive treatment effect (e.g., approximately 60% of the trials are 256 positive after 18 months in the case of three interim analyses; Figure 7A). On the other hand, the overall probability 257 of ending up with a negative trial due to more stringent analyses (i.e., less power) also increases, especially in the case 258 of immunotherapies with a weaker treatment effect ($\pm 57\%$ without an interim analysis vs. $\pm 63\%$ with three interim 259 analyses; Figure 7B). In an actual trial, the latter needs to be corrected by including additional patients to maintain the 260 pre-planned power. Furthermore, we observe that the timing of the interim analysis is crucial. Whereas an interim analysis 26 at 18 months provides additional value to the trial, interim analyses before 16 months are predicted to be wasteful due to 262 non-proportional hazards and less mature data. As a control, we simulated trials without any treatment effect. By design, 263 approximately 95% of the trials should end up negative irrespective of the number of interim analyses, which indeed 264 seemed to be the case (Figure 7C). Logically, the weaker the treatment effect, the higher the probability of erroneously 265 finding a harmful treatment effect – a characteristic that the simulation also exhibits (Figure 7B/C). 266



267

Figure 7: A priori scrutiny of the interim analysis plan to evaluate possible advantages and disadvantages of timed 268 additional analyses during the trial. (A) In the case of immunotherapy with a potent effect, in silico trials help develop 269 a rationale for the timing of the interim analyses. In these simulations, while an interim analysis at 12 months might not 270 add value to the trial, analyses after 16 and 18 months, respectively, have a probability of approximately 24% and 40% 271 to lead to early stopping with a positive result. (B) Multiple interim analyses can reduce the probability of confirming 272 the desired treatment effect in case of a weak immunotherapy effect. (C) In the absence of any treatment effect (a control 273 scenario), the number of interim analyses does not heavily influence the trial outcome. Each trial simulation contains 274 1200 patients (randomization ratio 1:1) to ensure adequate power of the trial. Trials are analyzed with a proportions test 275 (Pearson's chi-squared test). Treatment effect (fold increase of the T cell killing rate): strong = 12, weak = 4, no effect = 276 0 (see Methods). All simulations were performed using M1. 277

perpetuity. It is made available under a CC-BY 4.0 International license .

278 Discussion

Over the past decade, tumor-immune dynamics have been investigated extensively with *in silico* models. In the early 279 days of cancer immunotherapy, these modeling efforts focused – next to chemotherapy [37] – on cellular immunotherapy 280 [38, 39]. More recently, the field has addressed ICI therapy (e.g., [33, 40, 41]). Models of tumor-immune dynamics 281 have been applied to study pharmacokinetic and therapy dynamics (PK/PD), treatment effects (including mechanism(s) 282 of action, optimizing dosing regimens), treatment combinations, toxicity, biomarker prediction, drug resistance, and drug 283 discovery (see reviews on these topics [38, 42-47]). These extensive modeling efforts by the Mathematical Oncology 284 community have created a rich and valuable methodological resource. The goal of the work described in this paper is to 285 tap into this resource for the purpose of clinical trial design. Once parameterized, a mathematical model can predict likely 286 outcomes of treatments for individual patients; using such a model for trial design requires considering heterogeneity 287 between patients and translating these into likely survival curve shapes for each arm of the trial. 288

In this study, we leveraged mathematical models to perform cancer immunotherapy trials in silico, predicting survival 289 and response profiles of various treatment regimens. Complementary to conventional design methods, in silico trials 290 provide the ability to investigate the implications of a researcher's biological (as opposed to statistical) hypotheses about a 291 drug's mechanism of action for the design, conduct, analysis, and outcome of clinical trials. When comparing the simulated 292 outcomes to actual immunotherapy trial outcomes, we showed that in silico trials are suited to translate complex biological 293 mechanisms (such as those observed during the treatment of patients with ICI) into realistic trial outcomes. Crucially, 294 regardless of the model, the survival curves from these mechanism-based simulations reflected two pivotal components 295 often found in immunotherapy trials: a delayed curve separation and a plateauing tail of the survival curve at later stages 296 of the trial. In line with genuine immunotherapy trials, we find that these immunotherapy-specific response patterns differ 297 considerably from chemotherapy. Our findings confirm that diversity in survival curves profoundly impacts the outcomes 298 of immunotherapy trials [48]. Consequently, these features need to be considered when deciding on the sample size, 299 endpoint, randomization ratio, and the number and timing of interim analyses of a novel cancer immunotherapy trial. 300

In silico clinical trials are gaining popularity in medicine. Such trials enable investigating, among others, how novel drugs, 30 treatment schedules, dosing regimens, and inter-patient heterogeneity affect the outcome of a clinical trial [49]. In silico 302 clinical studies have a wide range of applicability from pediatric infectious [50] and orphan diseases [51] to diabetes [52], 303 inflammatory autoimmune diseases [53], traumatic injury [54], psychiatric illness [55], and cancer. In oncology, several in 304 silico clinical trials involving chemotherapy and tyrosine kinase inhibitors have been performed [56], [57]. Moreover, with 305 the onset of checkpoint inhibitors, in silico immunotherapy trials have gained interest, leading to trials with anti-CTLA-306 4-antibodies and anti-PD-(L)1 antibodies [58], [59], [60]. The common denominator in these trials is that they primarily 307 center on dosing regimens and treatment schedules. Herein lies the main difference with our simulation approach: although 308 the 'key ingredients' of these approaches are similar – they are based on a mathematical abstraction of a disease mechanism 309 - our trials do not aim to optimize treatment schedules. Instead, we complement traditional design methodology by adding 310 the means to predict key aspects of response and survival *a priori* to steer design decisions of novel immunotherapy trials. 311 These trials differ from traditional trial design research in that these, often statistically-grounded, approaches simulate 312 clinical trials based on population-level assumptions (e.g., with particular distributions of survival times, study durations, 313 or with a specific censoring mechanism). Examples of such high-level simulation approaches include, but are certainly not 314 limited to, studies aiming to calculate the sample size and power of clinical trials [61], [62], [63]. Since these methods lack 315 a direct link to the underlying biological disease mechanism, interpreting their parameters for individual trial participants 316 is difficult or even impossible. In contrast, in silico trials are founded on biological assumptions but then translate these 317 assumptions into statistical concepts such as hazard ratios. In this manner, simulated trials encourage an interdisciplinary 318

discussion about the design of an upcoming trial.

In silico clinical trials are applicable in several settings. First, they provide the means to verify clinical trial and treatment 320 assumptions before investing extensive amounts of work and funds into the development and execution of a clinical trial 321 and can, thereby, function as a proof of principle of the soundness of the hypotheses for an upcoming trial. Scrutiniz-322 ing each aspect of the trial design might lead to better design decisions and reduce unanticipated outcomes. Moreover, 323 this mechanism-based approach does not necessitate a deep understanding of complex mathematical theorems; instead, it 324 requires a biological understanding of a disease. This mechanistic basis is intuitive, which benefits the communication 325 between clinical doctors and biomedical researchers on the one hand and statisticians and clinical trialists on the other. 326 Additionally, in silico trials might serve as excellent educational tools. The ability to simulate a wide range - from basic 327 to highly advanced – research questions can be exploited in teaching activities for entry-level clinicians to experienced 328 trialists. A final implication, which holds for any trial simulation, is that they may provide some degree of insight when 329 conventional clinical trials are unfeasible due to practical or ethical constraints (e.g., clinical trials in rare diseases, pedi-330 atrics, or critical care medicine). 33

Nonetheless, *in silico* clinical trials have to be considered in light of some limitations. The most critical limitation is universal to any scientific model, whether *in vitro*, *in vivo*, or computational: the immunotherapy trial outcomes depend heavily (if not entirely) on the biological assumptions of the model, meaning that incorrect interactions or erroneous parametrization of the model can lead to inaccurate predictions. The parameterization, in particular, might pose a problem:

perpetuity. It is made available under a CC-BY 4.0 International license .

given the often novel treatment mechanisms, data to fine-tune the parameters of the model accurately might be scarce. In

these cases, the simulation itself can be used as a sensitivity analysis to assess to what extent a certain parameter range,

or the structure of the model itself, influences the robustness of the predictions. Our use of three different models in this

³³⁹ paper can be seen as such a type of sensitivity analysis; indeed, despite the major differences, it was reassuring to observe

that the models often agreed when it came to the critical qualitative aspects of the predicted survival curves.

In addition, while ODE models can be rather simple and intuitive to understand, translating biological principles into an

ODE model and implementing it into a simulation requires thorough knowledge of computational methods, potentially

limiting its widespread applicability. To address these limitations, we have made our model implementations available

as (1) an interactive website that can be used without installing any software and without any programming knowledge (https://computational-immunology.org/models/immunotherapy-trials/); (2) an R package allowing to run

(https://computational-immunology.org/models/immunotherapy-trials/); (2) an R package

simulations without requiring knowledge of ODEs and their solutions.

³⁴⁷ In summary, *in silico* cancer immunotherapy trials offer a versatile approach to simulate immunotherapy trials based on

biological assumptions. As a simulation tool, they facilitate the scrutiny of trial design decisions to optimize the probability
 of a successful immunotherapy trial and contribute to high-quality research for cancer patients.

perpetuity. It is made available under a CC-BY 4.0 International license .

350 Methods

Mechanism-based models of the tumor microenvironment

We implemented three ordinary differential equation (ODE) models of tumor-immune interactions: one from our previous work [27] and two by other authors [28, 29]. We first describe the common aspects of the models, then explain the

differences and show the model equations. All models describe cancer onset and progression, and we initialize each model by seeding a single growing tumor cell. This tumor cell divides, leading to a proliferating mass of tumor cells.

The parameter ρ controls the grows rate. Within the tumor microenvironment, an anti-tumor immune response induces

 $_{357}$ cytotoxic T cells to kill tumor cells at rate ξ . Intratumoral T cells die at a rate δ . In these models, the rate at which

T cells are activated and/or proliferate depends initially on the tumor size: an early stage microscopic tumor presents

fewer antigens than a larger – but still small – tumor. However, antigen presentation saturates as the tumor grows further (scaling factor T/(g+T) in Equations 3,4,3,9). Thus, four model parameters are shared between the models. Depending

on the parameter values, it is possible that the immune response eliminates the tumor or that the tumor escapes and grows

362 in an uncontrolled fashion.

We now discuss the model equations and parameters. In all models, we denote the number of tumor cells by T (Equations 1,5,8) and the number of intratumoral T cells by I (Equations 2,6,9). Compared to their original versions, variables and parameters in the equations below have been renamed, and the units of some parameters scaled to make the models easily comparable.

Model M1 is based on our previous work [27] and has the following equations:

$$\frac{dT}{dt} = \rho T^{\frac{3}{4}} - \xi I \frac{T}{1 + \frac{I}{h_I} + \frac{T}{h_T}}$$
(1)

$$\frac{dI}{dt} = m_S S - \delta I \tag{2}$$

$$\frac{dS}{dt} = \left(\frac{T}{g+T}\right)\left(\alpha_N N + p_S S\right) - m_S S \tag{3}$$

$$\frac{dN}{dt} = -\left(\frac{T}{g+T}\right)\alpha_N \tag{4}$$

We implemented a tumor growth rate that is slower than exponential growth. This is a common modeling choice based 368 on data and the biological premise that a growing tumor needs to sustain itself with nutrients. A common method to 369 implement a sub-exponential growth, which we adopt here, is to raise the number of tumor cells to the 3/4th power to 370 obtain the number of actively dividing cells [64]. We had previously modeled slightly faster-growing tumors using the 37 less common power 4/5th [27]. However, given that the other two models already implement faster-growing tumors, we 372 here use the more common, slower one. The killing of tumor cells is implemented using a double saturation model [65] 373 parameterized as proposed by Gadhamsetty et al. [66] (Michaelis constants h_T and h_I). The double saturation model 374 reflects that T cell killing of tumor cells takes hours [67]. The immune cells within the tumor microenvironment originate 375 from tumor-draining lymph nodes, where naive cytotoxic T cells (N, Equation 4) turn into activated T cells (S, activation 376 rate α_N ; Equation 4). Activated T cells proliferate at rate p_S and migrate to the tumor microenvironment to become 377 infiltrating T cells (I). The migration step leads to a slight delay between T cell activation and tumor cell killing on the 378 order of days ($m_S = 1 \text{day}^{-1}$). If desired, the distinction between lymph node and tumor microenvironment sites could 379 be removed for simplicity, given that the migration takes place on a faster timescale than the immune response. 380

Model M2, proposed by Tsur *et al.* [28], conceptually differs from M1 in five aspects. First, its tumor growth is unrestricted exponential. Second, the anti-tumor response saturates with increasing numbers of tumor cells but not with increasing numbers of T cells. Third, it explicitly represents antigen-presenting cells, called *A* (Equation 7), which are recruited at rate α_A in response to the tumor growth. Fourth, its T cells do not proliferate but are produced at a capped rate. Fifth, it does not distinguish between T cells in the lymph node and intratumoral T cells. As mentioned above, this is likely not critical. The model equations are as follows:

$$\frac{dT}{dt} = \rho T - \xi I \frac{T}{1 + \frac{T}{h_T}}$$
(5)

$$\frac{dI}{dt} = \alpha_e A - \delta I \tag{6}$$

$$\frac{dA}{dt} = \alpha_A \frac{T}{g+T} - \delta_A A \tag{7}$$

387

Model M3 was recently proposed by Bekker *et al.* [29]. It has two equations representing tumor cells and T cells. It resembles M2 in that tumor growth is initially exponential, but there is a maximum capacity for tumor cells (logistic

perpetuity. It is made available under a CC-BY 4.0 International license .

Model(s)	Symbol	Meaning	Unit
M1,M2,M3	ρ	Tumor proliferation rate	day^{-1}
M1,M2,M3	δ	T cell death rate	day^{-1}
M1,M2,M3	ξ	T cell killing rate	day^{-1} cell ⁻¹
M1,M2,M3	g	Amount of tumor cells at which antigen presentation is half-maximal	cell
M1,M2	h_T	Michaelis constant for tumor-dependent killing saturation	cell
M2,M3	α_A	T cell influx	cell day $^{-1}$
M1	h_I	Michaelis constant for T cell-dependent killing saturation	cell
M1	m_s	T cell migration rate	day^{-1}
M1	p_s	Proliferation rate of T cells in lymph nodes	day^{-1}
M1	α_N	Activation rate of naïve T cells	day^{-1}
M2	α_e	Production rate of intratumoral T cells	day^{-1}
M2	δ_A	Death rate of antigen-presenting cells	day^{-1}
M3	p_I	Proliferation rate of intratumoral T cells	day^{-1}
M3	β	Maximum number of tumor cells the body can sustain	cell
M3	ϵ	Rate at which tumor cells exhaust T cells	day^{-1} cell ⁻¹

Table 1: **Overview of parameters used in the three models.** Four parameters are shared between all models. The number of parameters is the largest for M1 at 9 parameters, followed by M2 and M3 (8).

growth). Killing dynamics follow a "mass-action law" (i.e., there is no saturation of the killing rate like in M1 and M2).
 Further, it includes a term for tumor size-dependent T cell exhaustion. This modeling choice leads to oscillating numbers

³⁹² of T cells and tumor cells in many parameter regimes. The model equations are as follows:

$$\frac{dT}{dt} = \rho T (1 - T/\beta) - \xi IT \tag{8}$$

$$\frac{dI}{dt} = \alpha_A + p_I I \frac{T}{g+T} - \delta I - \epsilon I T \tag{9}$$

393

412

413

414

415

416

417

418

We emphasize that M3 has been presented by Bekker *et al.* [29] as an abstraction of the general mechanisms underlying immunotherapy similar to M1; neither model claims to fit specific time-resolved data. Nevertheless, we included it as we were interested in the impact of the different modeling choices.

397 Model parameters

Table 1 shows an overview of the parameters in the three models. Four parameters appear in every model, but note that this does not necessarily mean that the parameters can be interpreted in the same way. For example, in a model where killing saturates in a scenario where there are many more tumor cells than T cells (M1 and M2), the same value of the killing rate will lead to less effective killing than in a model where there is no such saturation (M3). Other parameters are model-specific. To improve the inter-model comparability and reduce the potential for over-fitting, we left the parameters in all models fixed except the tumor growth rate ρ , which we varied to obtain heterogeneous patient populations.

Parameter values for M1 and M2 were taken from earlier publications [27,28], where the biological reasoning underlying 404 these values is explained, and references are provided. Differences in model structure, and in experimental data being 405 referred to, yield extensive variation in parameter values (Table 2). The variation in ρ is just a consequence of the different 406 tumor growth models, which give a different meaning to the parameter in each model. Despite the differences, the values 407 actually lead to comparable growth kinetics. The biggest quantitative differences are in the killing kinetics. M2's killing 408 rate ξ is three orders of magnitude smaller than M1's, but M2 compensates for this by saturating the killing at a number of 409 tumor cells that is five orders of magnitude higher than M1's. Overall, the amount of cells being killed when the immune 410 system is active and the tumor exceeds the diagnosis threshold is comparable across the models. 411

M3 was not explicitly parameterized by the authors [29]. Therefore, we set its parameters to the same values as in M1 or M2 as much as possible. For instance, because both M2 and M3 contain essentially unrestricted exponential growth of the tumor cells until M3 approaches the carrying capacity, we used the value for the tumor growth rate in M2 for M3. For the killing rate, we used a value that gave similar killing speed as M1 for tumors containing $10^9 - 10^{10}$ T cells. Note that due to the saturation term in M1, the killing is faster in M3 for larger tumors and slower for smaller tumors. Two parameters, the T cell exhaustion rate and the carrying capacity, were unique to M3. We set both to values that lead to a small influence of the corresponding terms on the simulation result and obtained comparable kinetics to the other two

⁴¹⁹ models at those parameter settings.

perpetuity. It is made available under a CC-BY 4.0 International license

Parameter	ρ	δ	ξ	g	h_T	α_A	h_I	m_S	p_S	α_N	α_e	δ_A	p_I	β	ϵ
M1	5	.019	.001	10000000	571		571	1	1	.0025					
M2	.045	.178	.00000134	92330	60095000	2073.5					.8318	.231			
M3	.045	.019	.0000000001	10000000		2073.5							0.05	$1.1 \cdot 10^{12}$	10^{-12}

Table 2: Fixed sarameter values used in our simulations. All values except ρ are taken from previous work, and are kept constant in all simulations. The value of ρ is allowed to vary between simulated patients to account for heterogeneity, and the distribution of ρ is fitted to real data. The values of ρ shown here were those used to generate Figure 2.

Parameter	ρ (log ₁₀ mean)	ρ (log ₁₀ sd)	chemotherapy effect	immunotherapy effect
M1	2.54	1.01	0.6	12.15
M2	-3.94	1.29	0.6	218.75
M3	-3.49	0.37	0.75	2.25

Table 3: Fitted parameter values used in Figure 5-Figure 7. The chemotherapy effect parameters were fixed and the other three parameters were then fitted using Approximate Bayesian Computation as described in the methods.

Simulating untreated disease, chemotherapy, and immunotherapy in individual patients 420

Using ODE models, we can implement different cancer immunotherapies in two general ways: (1) by changing model 42 parameters; (2) by adding or removing cells at a certain time. 422

Using this ODE model, we simulated cancer development and disease trajectories in patients. We extensively varied the 423 tumor properties (i.e., the tumor growth rate, the growth rate decline, and the decline decay rate) between patients to 424 generate interpatient variation in disease courses. 425

Each patient is simulated from cancer onset (i.e., malignant transformation of the first cell) for up to ten years. As argued 426 previously [27], we start from a diagnosis threshold of a tumor mass of 65×10^8 cells, corresponding to the size at which 427 common malignancies are diagnosed [68–70]. The lethal tumor burden is set to 10^{12} tumor cells (a tumor volume of ap-428

proximately 10.6 dm³). Since we expect both thresholds to vary considerably between patients, depending, for example, 429

on the timing of doctor visits or a tumor's location, we implement them as random variables that change with every sim-430

ulation. Specifically, every threshold is drawn from a log-normal distribution with a 4σ range of one order of magnitude. 431

The upper 2σ point (95.45% quantile) is set to 65×10^8 for diagnosis and 10^{12} for death. 432

Disease trajectories of patients with cancer can be steered with therapy. In our model, treatment is implemented by chang-433 ing the model parameters once the tumor exceeds the diagnosis threshold, as we assume this is when treatment starts. 434 Given their prominent roles in many oncological treatment plans, we included immune checkpoint inhibitors (ICI) and 435 chemotherapy in the models. Both treatments function through their primary modes of action. ICI are implemented by 436 increasing the killing rate of cytotoxic T cells (i.e., the parameter ξ) in M1 and M3. In M2, it is implemented by increasing 437 the T cell activation rate α_A and decreasing the death rate δ ; for simplicity, we restrict this such that the fold increase of 438 α_A equals the fold decrease of δ . These changes are implemented directly after diagnosis and remain active for the rest of 439 the simulation unless stated otherwise. The duration and potency of the ICI treatment (as measured by the magnitude of 440 the change of the affected parameters) eventually determine patient outcome. 441

In patients treated with chemotherapy, the immune system is still present; however, it is not boosted (as is the case during 442 ICI treatment). Hence, the T cells are not potent enough to curb tumor growth. We implement the cytotoxic capacity of 443 chemotherapy in the models uniformly by reducing the tumor growth rate (parameter ρ) to a smaller number. Again, the 444 duration and potency (as measured by the reduction in tumor growth rate) determine patient outcome. By default, the 445

treatment duration for ICI and chemotherapy are two years and six months, respectively. 446

Simulations of patient cohorts and parameter fitting 447

454

To generate heterogeneous patient populations, we draw each patient's growth rate parameter ρ from a log-normal distri-448 bution. Depending on the parameter, the simulated patient's tumor may clear spontaneously; such results are discarded 449 (rejection sampling). When the tumor reaches the diagnosis threshold, we apply ICI, chemotherapy, a combination of 450 chemotherapy and ICI, or we leave the patient untreated (i.e., a placebo treatment). Therefore, each patient cohort (Fig-451 ure 3) is characterized by two to four parameters: mean and standard deviation of the log tumor growth rate, immunother-452 apy treatment effect size, and chemotherapy treatment effect size. These two to four parameters can be fitted to a given 453 dataset.

Due to the stochastic nature of our model, we used an approximate Bayesian computation / sequential Monte Carlo (ABC-455

SMC) algorithm [71] to fit the parameters. As the test statistic for ABC-SMC, we used the root mean squared differ-456

ence (RMSD) between model-predicted and data-estimated survival curves (i.e., Kaplan-Meier curves) evaluated for each 457

month in a 2-year time window upon diagnosis. We set the sample size for generating the model-predicted survival curve 458

perpetuity. It is made available under a CC-BY 4.0 International license

- to the same number of patients that is contained in the data being fitted. Figure 3 and Supplementary Figure S1 show, 459 for each model, the simulation that achieved the lowest RMSD to the target data during each ABC run. 460
- We applied the ABC-SMC algorithm to all three patient cohorts shown in Figure 4. When examining the posterior distri-461
- butions of the parameters, we found that a wide range of chemotherapy effect values achieved comparable RMSD values 462
- for each model which is not surprising, given that a higher baseline growth rate combined with a higher chemotherapy 463
- effect leads to similar predicted tumor growth as a lower baseline growth rate combined with a lower chemotherapy effect. 464
- We therefore performed a further set of fits to the CA184-024 data where we kept the chemotherapy effect values fixed at 465
- 0.6 for M1 and M2 and at 0.75 for M3, respectively values that were chosen to obtain comparable and realistic impacts 466
- of chemotherapy on the 2-year OS curves (Figure 5A), and were plausible given the posterior distributions. We then 467
- again fitted the remaining three parameters to the CA184-024 data using ABC-SMC. By estimating the mode of the joint 468
- posterior distribution using kernel density smoothing, we obtained the parameter values shown in Table 3. 469

Simulating late-stage immunotherapy trials 470

Late-stage (i.e., phase III) clinical trials traditionally contain two arms: a control arm and a treatment arm. The control arm 471

can be a placebo (i.e., untreated) or a standard of care therapy. To construct phase III in silico immunotherapy trials, we 472

extended the simulations with treatment cohorts (mono-chemotherapy, mono-immunotherapy, chemoimmunotherapy, or 473

induction chemotherapy followed by immunotherapy). These cohorts facilitate the comparison between various treatment 474

regimens. The treatment cohort uses the same baseline distribution of tumor growth parameters as the control cohort. 475

Upon reaching the diagnosis threshold, up to two different treatments are applied in each arm; patients can be treated with 476

chemotherapy, ICI, combination therapy, or left untreated (as described above). Unless otherwise specified, the baseline 477

distribution of tumor growth parameters was derived from the most mature, digitized data from the CA184-024 trial, as 478 shown below [35]. 479

The primary endpoint of the trials is the 2-year OS. Given the absence of accrual times in *in silico* trials, the trial duration 480

equals two years, providing each virtual patient with 24 months of follow-up at the time of analysis. If the OS endpoint 481

is not reached for a patient (i.e., the patient's tumor burden does not reach the lethal volume within the time frame of the 482

simulated trial), the patient is considered censored for the endpoint and regarded as such in subsequent analyses. 483

Power and interim analysis simulations 484

To illustrate how the analysis method can affect the outcome of immunotherapy trials, we use several simulation approaches 485

to calculate the power of trials. Power simulations were performed as follows: a varying number of clinical trials were 486

simulated per data point. The survival data from each trial was analyzed with a log-rank test (dependent on the proportional 487 hazard assumption) or proportions test (Pearson's chi-squared test; independent of the proportional hazard assumption),

488 and we counted the number of positive trials (defined as p < 0.05). The percentage of positive trials indicates the power 489

of the trial. A harmful trial is defined as a positive trial with an effect size that favours untreated patients. 490

Data digitization & reconstruction 491

For some survival curves, the raw data was not available. Therefore, we extracted data points from the Kaplan-Meier 492

curves with WebPlotDigitizer 4.6 (https://apps.automeris.io/wpd/), and individual patient data was reconstructed 493 with the IPDfromKM package in R. 494

Analyses 495

Analyses and visualizations were performed in R. The complete list of R packages used throughout this manuscript is 496

provided in Supplementary Table S1. The R code used to perform all analyses is available at https://github.com/ 497 jtextor/insilico-trials. 498

Data availability 499

All simulated data used to generate the figures is available at this paper's GitHub repository at https://github.com/ 500

jtextor/insilico-trials. The digitized survival data from the CA184-024 and CheckMate 066 trials is also available 501 at the same repository. 502

Code availability 503

- C++ code that implements models M1, M2 and M3, and an R package that wraps the C++ code using Rcpp is available at 504
- this paper's GitHub repository at https://github.com/jtextor/insilico-trials/models/TumorImmuneModels/. 505
- The R code used to perform all analyses and generate all plots is also available at the same repository. An interactive, web-506
- based implementation of our models, written in Javascript and HTML, is available at https://computational-immunology. 507 org/models/immunotherapy-trials/. 508

References 509

- [1] Upadhaya S, Hubbard-Lucey VM, and Yu JX. Immuno-oncology drug development forges on despite covid-19. 510 Nature Reviews Drug Discovery, 19(11):751–752, 2020. doi:10.1038/d41573-020-00166-1. 511
- [2] Dowden H and Munro J. Trends in clinical success rates and therapeutic focus. *Nature Reviews Drug Discovery*, 512 18(7):495-496, 2019. doi:10.1038/d41573-019-00074-z. 513
- [3] Wong CH, Siah KW, and Lo AW. Estimation of clinical trial success rates and related parameters. *Biostatistics*, 514 20(2):273-286, 2018. doi:10.1093/biostatistics/kxx069. 515
- [4] BIO QA Informa Pharma Intelligence. Clinical development success rates and contributing factors. 516 https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020, 2021. 517
- [5] Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, and Kesselheim AS. Failure of investigational 518 drugs in late-stage clinical development and publication of trial results. JAMA Internal Medicine, 176(12):1826, 519 2016. doi:10.1001/jamainternmed.2016.6008. 520
- [6] de Miguel M and Calvo E. Clinical challenges of immune checkpoint inhibitors. *Cancer Cell*, 38(3):326–333, 2020. 521 doi:10.1016/j.ccell.2020.07.004. 522
- [7] Li A and Bergan RC. Clinical trial design: Past, present, and future in the context of big data and precision medicine. 523 Cancer, 126(22):4838-4846, 2020. doi:10.1002/cncr.33205. 524
- [8] Cousin S, Seneschal J, and Italiano A. Toxicity profiles of immunotherapy. Pharmacology & Therapeutics, 181:91-525 100, 2018. doi:10.1016/j.pharmthera.2017.07.005. 526
- [9] Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi 527 FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, and de Vries EGE. irecist: 528 guidelines for response criteria for use in trials testing immunotherapeutics. *The Lancet Oncology*, 18(3):e143–e152, 529 2017. doi:10.1016/s1470-2045(17)30074-8. 530
- [10] Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, and 531 Wolchok J. Improved endpoints for cancer immunotherapy trials. JNCI Journal of the National Cancer Institute, 532 102(18):1388–1397, 2010. doi:10.1093/jnci/djq310. 533
- [11] Chen TT. Statistical issues and challenges in immuno-oncology. Journal for Immuno Therapy of Cancer, 1(1), 2013. 534 doi:10.1186/2051-1426-1-18. 535
- [12] Mick R and Chen TT. Statistical challenges in the design of late-stage cancer immunotherapy studies. *Cancer* 536 Immunology Research, 3(12):1292-1298, 2015. doi:10.1158/2326-6066.cir-15-0260. 537
- [13] Rahman R, Fell G, Ventz S, Arfé A, Vanderbeek AM, Trippa L, and Alexander BM. Deviation from the propor-538 tional hazards assumption in randomized phase 3 clinical trials in oncology: Prevalence, associated factors, and 539 implications. Clinical Cancer Research, 25(21):6339–6345, 2019. doi:10.1158/1078-0432.ccr-18-3999. 540
- [14] Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer 54 U, Rhee I, Fine G, Winslow N, Chen DS, and Wolchok JD. Immune-modified response evaluation criteria in solid 542 tumors (imrecist): Refining guidelines to assess the clinical benefit of cancer immunotherapy. Journal of Clinical 543 Oncology, 36(9):850-858, 2018. doi:10.1200/jco.2017.75.1644. 544
- [15] Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey 545 R, and Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response 546 criteria. Clinical Cancer Research, 15(23):7412-7420, 2009. doi:10.1158/1078-0432.ccr-09-1624. 547
- [16] Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQ, and Forde PM. Immuno-548 oncology trial endpoints: Capturing clinically meaningful activity. *Clinical Cancer Research*, 23(17):4959–4969, 549 2017. doi:10.1158/1078-0432.ccr-16-3065. 550
- [17] Mushti SL, Mulkey F, and Sridhara R. Evaluation of overall response rate and progression-free survival as potential 55' surrogate endpoints for overall survival in immunotherapy trials. Clinical Cancer Research, 24(10):2268–2275, 552 2018. doi:10.1158/1078-0432.ccr-17-1902. 553
- [18] Chen TT. Milestone survival: A potential intermediate endpoint for immune checkpoint inhibitors. Journal of the 554 National Cancer Institute, 107(9):djv156, 2015. doi:10.1093/jnci/djv156. 555
- [19] Kaufman HL, Andtbacka RHI, Collichio FA, Wolf M, Zhao Z, Shilkrut M, Puzanov I, and Ross M. Durable response 556 rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. Journal for ImmunoTher-557 apy of Cancer, 5(1), 2017. doi:10.1186/s40425-017-0276-8. 558

- [20] Chan T, Yarchoan M, Jaffee E, Swanton C, Quezada S, Stenzinger A, and Peters S. Development of tumor mutation 559 burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of Oncology, 30(1):44-56, 2019. 560 doi:10.1093/annonc/mdy495. 56
- [21] Dudley JC, Lin MT, Le DT, and Eshleman JR. Microsatellite instability as a biomarker for pd-1 blockade. *Clinical* 562 Cancer Research, 22(4):813-820, 2016. doi:10.1158/1078-0432.ccr-15-1678. 563
- [22] Patel SP and Kurzrock R. Pd-11 expression as a predictive biomarker in cancer immunotherapy. *Molecular Cancer* 564 Therapeutics, 14(4):847-856, 2015. doi:10.1158/1535-7163.mct-14-0983. 565
- [23] Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, and Sinicrope FA. Tumor mutational burden as a predictive 566 biomarker in solid tumors. Cancer Discovery, 10(12):1808–1825, 2020. doi:10.1158/2159-8290.cd-20-0522. 567
- [24] Chen TT. Designing late-stage randomized clinical trials with cancer immunotherapy: Can we make it simpler? 568 Cancer Immunology Research, 6(3):250–254, 2018. doi:10.1158/2326-6066.cir-17-0465. 569
- [25] Royston P and Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and 570 analysis of randomized trials with a time-to-event outcome. BMC Medical Research Methodology, 13(1), 2013. 571 doi:10.1186/1471-2288-13-152. 572
- [26] Xu Z, Zhen B, Park Y, and Zhu B. Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics 573 in Medicine, 36(4):592-605, 2016. doi:10.1002/sim.7157. 574
- [27] Creemers JHA, Lesterhuis WJ, Mehra N, Gerritsen WR, Figdor CG, de Vries IJM, and Textor J. A tipping point in 575 cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. Journal 576 for ImmunoTherapy of Cancer, 9(5):e002032, 2021. doi:10.1136/jitc-2020-002032. 577
- [28] Tsur N, Kogan Y, Rehm M, and Agur Z. Response of patients with melanoma to immune checkpoint blockade in-578 sights gleaned from analysis of a new mathematical mechanistic model. Journal of Theoretical Biology, 485:110033, 579 2020. doi:10.1016/j.jtbi.2019.110033. 580
- [29] Bekker RA, Zahid MU, Binning JM, Spring BQ, Hwu P, Pilon-Thomas S, and Enderling H. Rethinking the im-58 munotherapy numbers game. Journal for ImmunoTherapy of Cancer, 10(7):e005107, 2022. doi:10.1136/jitc-2022-582 005107. 583
- [30] Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh 584 SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima 585 H, Kang YK, and Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal 586 junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer, 23(3):510-519, 2019. doi:10.1007/s10120-587 019-01034-7.
- [31] Hellmann MD, Paz-Ares L, Caro RB, Zurawski B, Kim SW, Costa EC, Park K, Alexandru A, Lupinacci L, de la 589 Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brah-590 mer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, and Rama-59[.] lingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. New England Journal of Medicine, 592 381(21):2020-2031, 2019. doi:10.1056/nejmoa1910231. 593
- [32] Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, 594 Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, 595 Baudelet C, and Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma 596 (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet, 397(10272):375–386, 2021. 597 doi:10.1016/s0140-6736(20)32714-8. 598
- [33] Tsur N, Kogan Y, Avizov-Khodak E, Vaeth D, Vogler N, Utikal J, Lotem M, and Agur Z. Predicting response to 599 pembrolizumab in metastatic melanoma by a new personalization algorithm. Journal of Translational Medicine, 600 17(1), 2019. doi:10.1186/s12967-019-2081-2. 60'
- [34] Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, Bartel J, Law M, Bateman M, and Klatt NE. 602 Prospective evaluation of prognostic variables from patient-completed questionnaires. north central cancer treatment 603 group. Journal of Clinical Oncology, 12(3):601–607, 1994. doi:10.1200/jco.1994.12.3.601. 604
- 605 [35] Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, and Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who 606 received ipilimumab plus dacarbazine in a phase III trial. Journal of Clinical Oncology, 33(10):1191-1196, 2015. 607 doi:10.1200/jco.2014.56.6018. 608
- [36] Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Giacomo AMD, Mortier L, Hassel JC, Rutkowski P, 609 McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni 610 V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, and 611

perpetuity. It is made available under a CC-BY 4.0 International license

- Atkinson V. Survival outcomes in patients with previously untreated braf wild-type advanced melanoma treated 612 with nivolumab therapy: Three-year follow-up of a randomized phase 3 trial. JAMA Oncology, 5(2):187, 2019. 613 doi:10.1001/jamaoncol.2018.4514. 614
- [37] Agur Z. From the evolution of toxin resistance to virtual clinical trials: the role of mathematical models in oncology. 615 Future Oncology, 6(6):917–927, 2010. doi:10.2217/fon.10.61. 616
- [38] Gupta SK, Jaitly T, Schmitz U, Schuler G, Wolkenhauer O, and Vera J. Personalized cancer immunotherapy using 617 systems medicine approaches. Briefings in Bioinformatics, 17(3):453-467, 2015. doi:10.1093/bib/bbv046. 618
- [39] Walker R and Enderling H. From concept to clinic: Mathematically informed immunotherapy. Current Problems in 619 Cancer, 40(1):68-83, 2016. doi:10.1016/j.currproblcancer.2015.10.004. 620
- [40] Butner JD, Elganainy D, Wang CX, Wang Z, Chen SH, Esnaola NF, Pasqualini R, Arap W, Hong DS, Welsh J, Koay 621 EJ, and Cristini V. Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint 622 inhibitor immunotherapy. Science Advances, 6(18), 2020. doi:10.1126/sciadv.aay6298. 623
- [41] Coletti R, Pugliese A, and Marchetti L. Modeling the effect of immunotherapies on human castration-resistant 624 prostate cancer. Journal of Theoretical Biology, 509:110500, 2021. doi:10.1016/j.jtbi.2020.110500. 625
- [42] Konstorum A, Vella AT, Adler AJ, and Laubenbacher RC. Addressing current challenges in cancer immunotherapy 626 with mathematical and computational modelling. Journal of The Royal Society Interface, 14(131):20170150, 2017. 627 doi:10.1098/rsif.2017.0150. 628
- [43] Brown LV, Gaffney EA, Wagg J, and Coles MC. Applications of mechanistic modelling to clinical and experimental 629 immunology: an emerging technology to accelerate immunotherapeutic discovery and development. Clinical and 630 Experimental Immunology, 193(3):284–292, 2018. doi:10.1111/cei.13182. 63
- [44] Yates JW, Byrne H, Chapman SC, Chen T, Cucurull-Sanchez L, Delgado-SanMartin J, Di Veroli G, Dovedi SJ, 632 Dunlop C, Jena R, Jodrell D, Martin E, Mercier F, Ramos-Montoya A, Struemper H, and Vicini P. Opportunities 633 for quantitative translational modeling in oncology. Clinical Pharmacology & Therapeutics, 108(3):447-457, 2020. 634 doi:10.1002/cpt.1963. 635
- [45] Agur Z, Halevi-Tobias K, Kogan Y, and Shlagman O. Employing dynamical computational models for 636 personalizing cancer immunotherapy. Expert Opinion on Biological Therapy, 16(11):1373–1385, 2016. 637 doi:10.1080/14712598.2016.1223622. 638
- [46] dePillis LG, Eladdadi A, and Radunskaya AE. Modeling cancer-immune responses to therapy. Journal of Pharma-639 cokinetics and Pharmacodynamics, 41(5):461–478, 2014. doi:10.1007/s10928-014-9386-9. 640
- [47] Craig M, Jenner AL, Namgung B, Lee LP, and Goldman A. Engineering in medicine to address the challenge of 641 cancer drug resistance: From micro- and nanotechnologies to computational and mathematical modeling. Chemical 642 Reviews, 121(6):3352-3389, 2020. doi:10.1021/acs.chemrev.0c00356. 643
- [48] Chen TT. Predicting analysis times in randomized clinical trials with cancer immunotherapy. BMC Medical Research 644 Methodology, 16(1), 2016. doi:10.1186/s12874-016-0117-3. 645
- [49] Alfonso S, Jenner AL, and Craig M. Translational approaches to treating dynamical diseases through in silico clinical 646 trials. Chaos: An Interdisciplinary Journal of Nonlinear Science, 30(12):123128, 2020. doi:10.1063/5.0019556. 647
- [50] Valitalo PAJ, van den Anker JN, Allegaert K, de Cock RFW, de Hoog M, Simons SHP, Mouton JW, and Knibbe 648 CAJ. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. Journal 649 of Antimicrobial Chemotherapy, 70(7):2074–2077, 2015. doi:10.1093/jac/dkv052. 650
- [51] Carlier A, Vasilevich A, Marechal M, de Boer J, and Geris L. In silico clinical trials for pediatric orphan diseases. 651 Scientific Reports, 8(1), 2018. doi:10.1038/s41598-018-20737-y. 652
- [52] Klinke DJ. Integrating epidemiological data into a mechanistic model of type 2 diabetes: Validating the prevalence 653 of virtual patients. Annals of Biomedical Engineering, 36(2):321-334, 2007. doi:10.1007/s10439-007-9410-y. 654
- [53] Schmidt BJ, Casey FP, Paterson T, and Chan JR. Alternate virtual populations elucidate the type i interferon signature 655 predictive of the response to rituximab in rheumatoid arthritis. BMC Bioinformatics, 14(1), 2013. doi:10.1186/1471-656 2105-14-221. 657
- [54] Brown D, Namas RA, Almahmoud K, Zaaqoq A, Sarkar J, Barclay DA, Yin J, Ghuma A, Abboud A, Con-658 stantine G, Nieman G, Zamora R, Chang SC, Billiar TR, and Vodovotz Y. Trauma in silico: Individual-659 specific mathematical models and virtual clinical populations. Science Translational Medicine, 7(285), 2015. 660 doi:10.1126/scitranslmed.aaa3636. 661

perpetuity. It is made available under a CC-BY 4.0 International license .

- [55] Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, and Russu A. Dosing and switching
 strategies for paliperidone palmitate 3-month formulation in patients with schizophrenia based on population phar macokinetic modeling and simulation, and clinical trial data. *CNS Drugs*, 31(4):273–288, 2017. doi:10.1007/s40263 017-0416-1.
- [56] Pérez-García VM, Ayala-Hernández LE, Belmonte-Beitia J, Schucht P, Murek M, Raabe A, and Sepúlveda J. Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas. *PLOS Computational Biology*, 15(7):e1006778, 2019. doi:10.1371/journal.pcbi.1006778.
- [57] Fassoni AC, Baldow C, Roeder I, and Glauche I. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. *Haematologica*, 103(11):1825–1834, 2018. doi:10.3324/haematol.2018.194522.
- [58] Jafarnejad M, Gong C, Gabrielson E, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, and Popel AS. A
 computational model of neoadjuvant PD-1 inhibition in non-small cell lung cancer. *The AAPS Journal*, 21(5), 2019.
 doi:10.1208/s12248-019-0350-x.
- [59] Milberg O, Gong C, Jafarnejad M, Bartelink IH, Wang B, Vicini P, Narwal R, Roskos L, and Popel AS. A QSP model
 for predicting clinical responses to monotherapy, combination and sequential therapy following CTLA-4, PD-1, and
 PD-11 checkpoint blockade. *Scientific Reports*, 9(1), 2019. doi:10.1038/s41598-019-47802-4.
- [60] Wang H, Milberg O, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, Santa-Maria CA, and Popel AS. In
 silico simulation of a clinical trial with anti-ctla-4 and anti-pd-11 immunotherapies in metastatic breast cancer using
 a systems pharmacology model. *Royal Society Open Science*, 6(5):190366, 2019. doi:10.1098/rsos.190366.
- [61] Bang H, Jung SH, and George SL. Sample size calculation for simulation-based multiple-testing procedures. *Journal of Biopharmaceutical Statistics*, 15(6):957–967, 2005. doi:10.1080/10543400500265710.
- [62] Doostfatemeh M, Ayatollah SMT, and Jafari P. Power and sample size calculations in clinical trials with patient reported outcomes under equal and unequal group sizes based on graded response model: A simulation study. *Value in Health*, 19(5):639–647, 2016. doi:10.1016/j.jval.2016.03.1857.
- [63] Wilson DT, Hooper R, Brown J, Farrin AJ, and Walwyn RE. Efficient and flexible simulation-based sample size
 determination for clinical trials with multiple design parameters. *Statistical Methods in Medical Research*, 30(3):799–
 815, 2020. doi:10.1177/0962280220975790.
- [64] West GB, Brown JH, and Enquist BJ. A general model for ontogenetic growth. *Nature*, 413(6856):628–631, 2001.
 doi:10.1038/35098076.
- [65] Borghans JAM, de Boer RJ, and Segel LA. Extending the quasi-steady state approximation by changing variables.
 Bulletin of Mathematical Biology, 58(1):43–63, 1996. doi:10.1007/bf02458281.
- ⁶⁹³ [66] Gadhamsetty S, Marée A, Beltman J, and de Boer R. A general functional response of cytotoxic t lymphocyte-⁶⁹⁴ mediated killing of target cells. *Biophysical Journal*, 106(8):1780–1791, 2014. doi:10.1016/j.bpj.2014.01.048.
- [67] Weigelin B, den Boer AT, Wagena E, Broen K, Dolstra H, de Boer RJ, Figdor CG, Textor J, and Friedl P. Cytotoxic
 t cells are able to efficiently eliminate cancer cells by additive cytotoxicity. *Nature Communications*, 12(1), 2021.
 doi:10.1038/s41467-021-25282-3.
- [68] Moreno CC, Mittal PK, Sullivan PS, Rutherford R, Staley CA, Cardona K, Hawk NN, Dixon WT, Kitajima HD, Kang
 J, Small WC, Oshinski J, and Votaw JR. Colorectal cancer initial diagnosis: Screening colonoscopy, diagnostic
 colonoscopy, or emergent surgery, and tumor stage and size at initial presentation. *Clinical Colorectal Cancer*,
 15(1):67–73, 2016. doi:10.1016/j.clcc.2015.07.004.
- [69] Zastrow S, Phuong A, von Bar I, Novotny V, Hakenberg OW, and Wirth MP. Primary tumor size in renal cell cancer
 in relation to the occurrence of synchronous metastatic disease. Urologia Internationalis, 92(4):462–467, 2014.
 doi:10.1159/000356325.
- [70] Ball DL, Fisher RJ, Burmeister BH, Poulsen MG, Graham PH, Penniment MG, Vinod SK, Krawitz HE, Joseph DJ,
 Wheeler GC, and McClure BE. The complex relationship between lung tumor volume and survival in patients with
 non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study
 of the trans-tasman radiation oncology group (TROG 99.05). *Radiotherapy and Oncology*, 106(3):305–311, 2013.
 doi:10.1016/j.radonc.2012.12.003.
- [71] Sisson SA, Fan Y, and Tanaka MM. Sequential monte carlo without likelihoods. *Proceedings of the National Academy of Sciences*, 104(6):1760–1765, 2007. doi:10.1073/pnas.0607208104.
- [72] Paola Rebora AS and Reilly M. *bshazard: Nonparametric Smoothing of the Hazard Function*, 2018. R package version 1.1.

- [73] Wickham H, François R, Henry L, and Müller K. *dplyr: A Grammar of Data Manipulation*, 2022. R package version
 1.0.10.
- ⁷¹⁶ [74] Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2016.
- [75] Sjoberg D. ggsankey: Sankey, Alluvial and Sankey Bump Plots, 2022. R package version 0.0.99999.
- [76] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2022.
- [77] Liu N and Lee J. *IPDfromKM: Map Digitized Survival Curves Back to Individual Patient Data*, 2020. R package version 0.1.10.
- [78] Duong T. ks: Kernel Smoothing, 2022. R package version 1.13.5.
- [79] Casper C, Cook T, and Perez. OA. *Idbounds: Lan-DeMets Method for Group Sequential Boundaries*, 2022. R
 package version 2.0.0. Based on FORTRAN program Id98.
- [80] Eddelbuettel D and François R. Rcpp: Seamless R and C++ integration. *Journal of Statistical Software*, 40(8):1–18, 2011. doi:10.18637/jss.v040.i08.
- [81] Terry M. Therneau and Patricia M. Grambsch. *Modeling Survival Data: Extending the Cox Model*. Springer, New York, 2000.
- [82] Kassambara A, Kosinski M, and Biecek P. *survminer: Drawing Survival Curves using 'ggplot2'*, 2021. R package version 0.4.9.

List of abbreviations 731

- ICI: immune checkpoint inhibitor; NCCTG: North Central Cancer Treatment Group; ODE: ordinary differential equation; 732
- OS: overall survival; PHA: proportional hazard assumption. 733

734 **Declarations**

735 Ethics approval and consent to participate

736 Not applicable.

737 Consent for publication

738 Not applicable.

739 Competing interests

740 Not applicable.

741 Funding

JC was funded by the Radboudumc. CF received an ERC Adv Grant ARTimmune (834618) and an NWO Spinoza grant.

- ⁷⁴³ IV received an NWO-Vici grant (918.14.655). JT and AA were supported by a Young Investigator Grant (10620) from
- the Dutch Cancer Society. JT and GS were also supported by NWO grant VI.Vidi.192.084.

745 Author contributions

JHAC and JT conceived this study. JHAC, AA and JT performed the experiments. JHAC and JT wrote the manuscript.
 All authors provided feedback on the manuscript and reviewed the manuscript prior to submission.

748 Acknowledgements

⁷⁴⁹ We thank Shabaz Sultan for his help with implementing the web-based frontend for performing simulations.

Supplementary Figures 750



Supplementary Figure S1: Fits of models M2 and M3 to three survival datasets from clinical trials (compare to Figure 3).



Supplementary Figure S2: In silico chemotherapy trial that approximately fulfills the proportional hazards assumption.



Supplementary Figure S3: Predicted immunotherapy trial survival curves for model M2 based on its fit to the CA184-024 trial data.



Supplementary Figure S4: Predicted immunotherapy trial survival curves for model M3 based on its fit to the CA184-024 trial data.



Supplementary Figure S5: Power analyses for chemotherapy vs. placebo and chemoimmunotherapy vs. immunotherapy trials using all three models.

R package	Reference	Version	Source
bshazard	[72]	1.1	CRAN
dplyr	[73]	1.0.10	CRAN
ggplot2	[74]	3.3.6	CRAN
ggsankey	[75]	0.0.99999	github.com/davidsjoberg/ggsankey
grid	[76]	4.2.0	part of R 4.2.0
IPDfromKM	[77]	0.1.10	CRAN
ks	[78]	1.13.5	CRAN
ldbounds	[79]	2.0.0	CRAN
Rccp	[80]	1.0.9	CRAN
survival	[81]	3.3-1	CRAN
survminer	[82]	0.4.9	CRAN

Supplementary Table S1: R packages used in this manuscript with references and versions.